Inhibitor of Fc-Frizzled-8 receptor antagonizing Wnt signaling. Sequential combined treatment is well-tolerated but has limited efficacy. The ORR was 76%. Median PFS was 10.3 months and OS was 33 monthsInhibitor of PORCN that lowers secretion and binding of Wnt to its receptor. Combined therapy caused cell cycle arrest and cytotoxicity of cells isolated from ascites of patients with HGSOCmoAB that inhibits Wnt pathway by targeting the Frizzled receptors on cancer cells. Treatment with vantictumab before paclitaxel therapy sensitizes cancer cells to death. Here, PORCN is linked to cancer.